Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 5 minute read Pharma Industry News Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables. byPallavi MadhirajuJune 21, 2025